Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study
Fig 2
Stratification of patients with mid-regional pro-adrenomedullin (MR-proADM) levels greater or less than 1.8 nmol/L at ICU admission.